Aryl-Substituted Nitrogen Heterocyclic Compounds for Nociceptin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current substances fail to effectively inhibit nociceptin binding to the ORL1 receptor, which is crucial for managing pain, opioid tolerance, and various neurological disorders, leading to inadequate treatment options for conditions like cancerous pain, morphine tolerance, and cognitive impairments.
Innovation Solution
Development of aryl-substituted nitrogen-containing heterocyclic compounds that specifically inhibit nociceptin binding to the ORL1 receptor, offering potential as analgesics, anti-addiction agents, and treatments for cognitive and neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current substances are used to inhibit nociceptin binding to ORL1 receptor, then treatment options for pain and neurological disorders are limited, but the effectiveness of nociceptin binding inhibition is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying substituent parameters (R1, R2, R3, R4) on the nitrogen-containing heterocyclic core structure to optimize nociceptin binding inhibition. Different combinations of substituents (fluoro, chloro, nitro, hydroxyl, methoxy groups at various positions) were tested to achieve enhanced binding affinity and selectivity for ORL1 receptor, directly resolving the insufficiency of current substances
Solution Approach 2:
The patent employs composite material principles by creating a series of hybrid compounds that combine the nitrogen-containing heterocyclic scaffold with diverse aromatic and aliphatic substituents. This composite approach allows integration of multiple functional groups (electron-withdrawing, electron-donating, hydrophobic, hydrophilic) into single molecules, achieving both high binding inhibition effectiveness and expanded therapeutic applicability
2Reliability
If aryl-substituted nitrogen-containing heterocyclic compounds are developed to specifically inhibit nociceptin binding, then analgesic effects and cognitive function improvement are achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: a core nitrogen-containing heterocyclic structure (providing basic binding capability) and multiple substituent segments (R1-R4) that can be independently optimized. This modular segmentation allows systematic structure-activity relationship studies and simplifies the design process despite the overall molecular complexity
Solution Approach 2:
The patent implements local quality by assigning specific functional characteristics to different regions of the molecule. For example, electron-withdrawing groups (F, Cl, NO2) are placed at specific positions to enhance binding affinity, while hydroxyl or methoxy groups are positioned to improve solubility or specific receptor interactions. Each substituent location (R1-R4) is optimized independently to achieve its local function while contributing to the overall therapeutic effect
Data Source
AI summary
Disclosed is an aryl-substituted nitrogen-containing heterocyclic compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof. This compound serves as nociceptin receptor antagonist and is useful as a pharmaceutical agent for treating diseases associated with a nociceptin receptor. (I) [in the formula, A1, A2 and A3 independently represent a carbon atom or a nitrogen atom, and one or two of A1, A2 and A3 represent a carbon atom; R1 represents a lower alkyl group or the like; R2 represents a phenyl group which may be substituted with a halogen atom or the like; R3 represents a hydrogen atom, a lower alkyl group or the like; and R4 represents a lower alkyl group or the like.]